LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases

被引：0
|
作者：
Amanda E. D. Van Swearingen
Marni B. Siegel
Allison M. Deal
Maria J. Sambade
Alan Hoyle
D. Neil Hayes
Heejoon Jo
Paul Little
Elizabeth Claire Dees
Hyman Muss
Trevor Jolly
Timothy M. Zagar
Nirali Patel
C. Ryan Miller
Joel S. Parker
J. Keith Smith
Julie Fisher
Nikita Shah
Lisle Nabell
Rita Nanda
Patrick Dillon
Vandana Abramson
Lisa A. Carey
Carey K. Anders
机构：
[1] University of North Carolina at Chapel Hill,Lineberger Comprehensive Cancer Center
[2] Carolinas Medical Center,West Cancer Center
[3] MD Anderson Orlando,undefined
[4] University of Alabama,undefined
[5] University of Chicago,undefined
[6] University of Virginia,undefined
[7] Vanderbilt University,undefined
[8] University of Tennessee,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 171卷
关键词：
Breast cancer; Brain metastases; Metastases; PI3K, MEK; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：637 / 648
页数：11
相关论文
共 50 条
  • [1] LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
    Van Swearingen, Amanda E. D.
    Siegel, Marni B.
    Deal, Allison M.
    Sambade, Maria J.
    Hoyle, Alan
    Hayes, D. Neil
    Jo, Heejoon
    Little, Paul
    Dees, Elizabeth Claire
    Muss, Hyman
    Jolly, Trevor
    Zagar, Timothy M.
    Patel, Nirali
    Miller, C. Ryan
    Parker, Joel S.
    Smith, J. Keith
    Fisher, Julie
    Shah, Nikita
    Nabell, Lisle
    Nanda, Rita
    Dillon, Patrick
    Abramson, Vandana
    Carey, Lisa A.
    Anders, Carey K.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (03) : 637 - 648
  • [2] LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases
    Anders, Carey K.
    Deal, Allison Mary
    Dees, Elizabeth Claire
    Irvin, William Johnson
    Muss, Hyman Bernard
    Noe, Jeanne
    Karginova, Olga
    Adamo, Barbara
    Prat, Aleix
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+breast cancer brain metastases (BCBM).
    Anders, Carey K.
    Deal, Allison Mary
    Van Swearingen, Amanda Elyse Day
    Siegel, Marni
    Hayes, David N.
    Jo, Heejoon
    Little, Paul
    Dees, Elizabeth Claire
    Muss, Hyman B.
    Jolly, Trevor Augustus
    Zagar, Timothy
    Smith, J. Keith
    Fisher, Julie Gottlieb
    Shah, Nikita C.
    Nabell, Lisle
    Nanda, Rita
    Dillon, Patrick Michael
    Puhalla, Shannon
    Abramson, Vandana Gupta
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [5] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [6] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
    Lucas Bayo-Calero, Juan
    Mayordomo, Jose I.
    Salnchez-Rovira, Pedro
    Perez-Carrion, Ramon
    Illaramendi, Jose J.
    Garcia-bueno, Jose M.
    Gonzalez-Flores, Encarnacion
    Crespo, Carmen
    Ramos-Vazquez, Manuel
    Garcia-Palomo, Andres
    Ruiz-Borrego, Manuel
    de la Haba, Juan
    Gomez-Bernal, Amalia
    Yubero-Esteban, Alfonso
    CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
  • [7] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
  • [8] A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Sperinde, J.
    Huang, W.
    Chen, W. Y.
    Savoie, J.
    Fornier, M.
    Winer, E. P.
    Bunnell, C.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1841 - 1847
  • [9] Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
    Lin, Nancy U.
    Pegram, Mark
    Sahebjam, Solmaz
    Ibrahim, Nuhad
    Fung, Anita
    Cheng, Anna
    Nicholas, Alan
    Kirschbrown, Whitney
    Kumthekar, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (24) : 2667 - +
  • [10] Brain metastases in HER2-positive breast cancer
    Lin, Nancy U.
    LANCET ONCOLOGY, 2013, 14 (03): : 185 - 186
12345